Raynauds Disease - Pipeline Review, H2 2016

Date: August 24, 2016
Pages: 53
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RCDA4032CA1EN
Leaflet:

Download PDF Leaflet

Raynauds Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Raynauds Disease - Pipeline Review, H2 2016’, provides an overview of the Raynauds Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Raynauds Disease
  • The report reviews pipeline therapeutics for Raynauds Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Raynauds Disease therapeutics and enlists all their major and minor projects
  • The report assesses Raynauds Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Raynauds Disease
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Raynauds Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Raynauds Disease Overview
Therapeutics Development
Pipeline Products for Raynauds Disease - Overview
Raynauds Disease - Therapeutics under Development by Companies
Raynauds Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Raynauds Disease - Products under Development by Companies
Raynauds Disease - Companies Involved in Therapeutics Development
Allergan Plc
Apricus Biosciences, Inc.
Covis Pharmaceuticals, Inc.
Human Stem Cells Institute
Raynauds Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acetylcysteine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alprostadil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELS-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neovasculgen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroglycerin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Raynauds Disease - Dormant Projects
Raynauds Disease - Discontinued Products
Raynauds Disease - Product Development Milestones
Featured News & Press Releases
Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference
Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros
Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference
Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May
Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa
Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon
Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa
Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon
Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana
May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon
Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa
Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma
Jan 10, 2006: MediQuest Therapeutics Receives Special Protocol Assessment From The U.S. FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Raynauds Disease, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Raynauds Disease - Pipeline by Allergan Plc, H2 2016
Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H2 2016
Raynauds Disease - Pipeline by Covis Pharmaceuticals, Inc., H2 2016
Raynauds Disease - Pipeline by Human Stem Cells Institute, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Raynauds Disease - Dormant Projects, H2 2016
Raynauds Disease - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Raynauds Disease, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Gaucher's Disease - Pipeline Review, H2 2015 US$ 1,600.00 Aug, 2015 · 86 pages

Ask Your Question

Raynauds Disease - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: